<DOC>
	<DOCNO>NCT01067235</DOCNO>
	<brief_summary>The objective study evaluate compare efficacy safety escalate dos BF2.649 BF2.649 add Modafinil cataplexy patient narcolepsy</brief_summary>
	<brief_title>Efficacy Safety Study BF2.649 BF2.649 Add Modafinil Cataplexy Patients With Narcolespy</brief_title>
	<detailed_description>BF 2.649 , new molecule , reduce significantly diurnal sleepiness demonstrate anti-cataplexy effect pre-clinical clinical study . The objective POC study firstly evaluate compare efficacy safety escalate dos BF2.649 BF2.649 add Modafinil ( 200 mg/day ) cataplexy attack , secondly evaluate additive/synergistic effect safety combination BF2.649 Modafinil EDS assess objective subjective measure include ESS , MWT , patient sleep diary .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>`` De novo '' patient newly diagnose narcolespy cataplexy , take treatment Excessive Daytime Sleepiness ( EDS ) cataplexy patient previously diagnose narcolepsy cataplexy take treatment EDS cataplexy 3 month partial total cataplexy attack frequency least 5 per week 14 day baseline period ESS &gt; or= 14 end baseline period Patients unable unwilling temporarily discontinue noauthorized drug substance Current recent history substance abuse dependence disorder include alcohol abuse Psychiatric neurological disorder psychosis dementia , bipolar illness , severe anxiety , clinical depression , history seizure disorder problem investigator 's opinion would preclude patient 's participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Narcolespy</keyword>
	<keyword>Cataplexy</keyword>
	<keyword>Excesssive daytime Sleepiness</keyword>
	<keyword>Sleep Disorders</keyword>
	<keyword>Sleep attack</keyword>
	<keyword>Orphan Drug</keyword>
	<keyword>Pitolisant</keyword>
</DOC>